Utilization of testing for activated protein C resistance in a reference laboratory

American Journal of Clinical Pathology

Volumn 106, Issue 2, 1996, Pages 248-252

  Florell, Scott R ^a,c   Rodgers III, George M ^a,b,c  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ARUP LABORATORIES   (United States)

Author keywords

Activated protein C resistance; APC resistance; Factor V Leiden; Inherited thrombosis

Indexed keywords

ACTIVATED PROTEIN C;

ADULT; ANTICOAGULATION; ANTITHROMBIN III DEFICIENCY; ARTICLE; FEMALE; GENE MUTATION; HUMAN; INHERITANCE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOPHILIA; THROMBOSIS;

EID: 0029821252     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/106.2.248     Document Type: Article

References (17)

1. Samaha M, Trossaert M, Conard J, et al. Prevalence and patient profile in activated protein C resistance. Am J Clin Pathol 1995;104:450-454.
2. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993;342:1503-1506.
3. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-522.
4. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993;82:1989-1993.
5. Rodgers GM, Chandler WL. Laboratory and clinical aspects of inherited thrombotic disorders. Am J Hematol 1992;41:113-122.
6. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb Vasc Biol 1992;12:135-145.
7. Bertina RM, Koelman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
8. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci 1993;90: 1004-1008.
9. Rodgers GM. Activated protein C resistance and inherited thrombosis. Am J Clin Pathol 1995;103:261-262.
10. Bick RL, Ancypa D. Blood protein defects associated with thrombosis. Laboratory assessment. Clin Lab Med 1995;15:125-63.
11. Dahlback B. Molecular genetics of thrombophilia: Factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state. J Lab Clin Med 1995;125:566-71.
12. Bokarewa MI, Falk G, Sten-Linder M, et al. Thrombotic risk factors and oral contraception. J Lab Clin Med 1995;126(3):294-298.
13. Cushman M, Bovill EG, Tracey RP. Activated protein C resistance and inherited thrombosis. Am J Clin Pathol 1995;104:357-358.
14. Ward K. Personal communication, unpublished data.
15. de Ronde H, Bertina RM. Laboratory diagnosis of APC resistance: A critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994;72:880-886.
16. Tosetto A, Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 1995;73:732-733.
17. Le DT, Griffin JH, Greengard JS, et al. Use of a generally applicable tissue factor-dependent Factor V assay to detect activated protein C-resistant Factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 1995;85:1704-1711.